New treatments for bipolar disorder: The role of atypical neuroleptic agents

Journal of Clinical Psychiatry

Volumn 61, Issue SUPPL. 14, 2000, Pages 33-42

  Ghaemi, S N ^a  

^a CAMBRIDGE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; DEPRESSION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; MANIA; MANIC DEPRESSIVE PSYCHOSIS; MOOD; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; TREATMENT PLANNING; WEIGHT GAIN;

ACUTE DISEASE; ALGORITHMS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; CLOZAPINE; DIBENZOTHIAZEPINES; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM; PIRENZEPINE; PSYCHOTIC DISORDERS; RISPERIDONE; TREATMENT OUTCOME; VALPROIC ACID;

EID: 0034500541     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. The emergency treatment of depression complicated by psychosis or agitation
2. Prophylactic lithium carbonate with and without imipramine for bipolar 1 patients
3. Lithium prophylaxis in recurrent affective illness
4. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders
5. Can antidepressants cause mania and worsen the course of affective illness?
6. Course of the manic-depressive cycle and changes caused by treatments
7. Antidepressant-induced mania and cycle acceleration: A controversy revisited
8. Is bipolar disorder still underdiagnosed? Are antidepressants overutilized?
9. Flupenthixol decanoate in recurrent manic depressive illness: A comparison with lithium
10. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients
11. A double-blind comparison of lithium carbonate and maprotiline in the prophylaxis of the affective disorders
12. Adjunctive clonazepam for maintenance treatment of bipolar affective disorder
13. Neuroleptic exposure following inpatient treatment of acute mania with lithium and neuroleptic
14. Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder
15. Bipolar mood disorder: Practical strategies for acute and maintenance phase treatment
16. New concepts in mood stabilization: Evidence of the effectiveness of valproate and lamotrigine
17. Mood stabilizers and the evolution of maintenance study designs in bipolar I disorder
18. Clozapine in severe mood disorders
19. Clozapine for treatment-refractory mania
20. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania
21. Clozapine and bipolar disorder
22. Clinical management of clozapine patients in relation to efficacy and side-effects
23. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia
24. Clozapine in the treatment of dysphoric mania
25. Risperidone in the treatment of affective illness and obsessive-compulsive disorder
26. Risperidone in the treatment of mania
27. Acute treatment of bipolar disorder with adjunctive risperidone in outpatients
28. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder
29. Long-term risperidone treatment in bipolar disorder: 6-month follow-up
30. Risperidone therapy in treatment refractory acute bipolar and schizoaffective mania
31. Risperidone compared with both lithium and haloperidol in mania: A double-blind randomized controlled trial
32. Efficacy and safety of risperidone in bipolar disorders
33. A rating scale for mania: Reliability, validity, and sensitivity
34. A rating scale for depression
35. Depression during mania: Clinical observations and theoretical implications
36. Schizoaffective patients
37. Risk of reoccurrence following discontinuation of lithium treatment in bipolar disorder
38. Pharmacological profile of risperidone
39. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia
40. Olanzapine in treatment-resistant bipolar disorder
41. Olanzapine vs placebo in the treatment of acute mania
42. Long-term olanzapine treatment of mania: Improvement in mood symptoms and cognitive function
43. Use of antipsychotics in bipolar disorder
44. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): The CGI-BP
45. Clinical predictors of acute response with olanzapine in psychotic mood disorders
46. The use of quetiapine for treatment-resistant bipolar disorder: A case series
47. Quetiapine fumurate in neuroleptic-dependent mood disorders
48. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder
49. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment
50. Clinical review of risperidone
51. Risperidone: A new, novel (and better?) antipsychotic
52. Risperidone: Clinical safety and efficacy in schizophrenia
53. Clozapine: Guidelines for clinical management
54. Clozapine for the treatment-resistant schizophrenic
55. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics
56. Prevalence and severity of akathisia in patients on clozapine
57. The risks and benefits of clozapine versus chlorpromazine
58. The prevalence of akathisia in patients receiving stable doses of clozapine
59. Prevalence of spontaneous dyskinesia in schizophrenia
60. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications
61. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol
62. Does clozapine cause tardive dyskinesia?
63. Risperidone-induced tardive dyskinesia
64. Clozapine: Neuroleptic-induced EPS and tardive dyskinesia
65. Clozapine-related tardive dyskinesia
66. Schizophrenia and severe tardive dyskinesia responsive to risperidone
67. Clinical efficacy of risperidone in a patient with severe tardive dyskinesia
68. Risperidone treatment in tardive dystonia
69. Effects of risperidone in tardive dyskinesia: An analysis of the Canadian multicenter risperidone study
70. Novel antipsychotics: Comparison of weight gain liabilities
71. The relationship of pharmacology to side effects
72. A double-blind trial of bupropion versus desipramine for bipolar depression
73. Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients
74. Possible induction of mania and hypomania by olanzapine or risperidone: A critical review of reported cases